Identification and validation of the PARP inhibitor-related gene KANK3 for predicting prognosis and immunotherapeutic response in prostate cancer.

ABSTRACT: Background: Prostate cancer (PCa), a prevalent malignant neoplasm in men, has its biochemical recurrence-free survival (BCRFS) serving as a critical determinant for patient prognosis. PARP inhibitors have demonstrated potential therapeutic value in the management of PCa. Nevertheless, the precise influence exerted by their associated genes on BCRFS remains elusive. Methods: We selected the differentially expressed genes after treatment with olaparib and defined them as PARP inhibitor-related genes (PIRGs). Consensus clustering was employed to evaluate the relationships among different PIRGs clusters, prognosis, and the immune microenvironment. Univariate COX regression analysis was used to screen the prognosis-related PIRGs, which were then incorporated into multiple machine

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC12491201 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature